M

MaxCyte Inc
NASDAQ:MXCT

Watchlist Manager
MaxCyte Inc
NASDAQ:MXCT
Watchlist
Price: 3.55 USD 2.9% Market Closed
Market Cap: 374.5m USD
Have any thoughts about
MaxCyte Inc?
Write Note

MaxCyte Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

MaxCyte Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
M
MaxCyte Inc
NASDAQ:MXCT
Retained Earnings
-$175.8m
CAGR 3-Years
-23%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Retained Earnings
$51.4B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
18%
Danaher Corp
NYSE:DHR
Retained Earnings
$43.3B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
8%
Mettler-Toledo International Inc
NYSE:MTD
Retained Earnings
$8.1B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
14%
Agilent Technologies Inc
NYSE:A
Retained Earnings
$773m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
-19%
IQVIA Holdings Inc
NYSE:IQV
Retained Earnings
$5.6B
CAGR 3-Years
43%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

MaxCyte Inc
Glance View

Market Cap
373.8m USD
Industry
Life Sciences Tools & Services

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

MXCT Intrinsic Value
3.35 USD
Overvaluation 6%
Intrinsic Value
Price
M

See Also

What is MaxCyte Inc's Retained Earnings?
Retained Earnings
-175.8m USD

Based on the financial report for Dec 31, 2023, MaxCyte Inc's Retained Earnings amounts to -175.8m USD.

What is MaxCyte Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-20%

Over the last year, the Retained Earnings growth was -27%. The average annual Retained Earnings growth rates for MaxCyte Inc have been -23% over the past three years , -20% over the past five years .

Back to Top